Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis
about
Gene delivery to adipose tissue using transcriptionally targeted rAAV8 vectorsAntifibrotic effect of MMP13-encoding plasmid DNA delivered using polyethylenimine shielded with hyaluronic acidRecombinant AAV-directed gene therapy for type I glycogen storage diseases.Kidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9.Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene deliveryRenal rescue of dopamine D2 receptor function reverses renal injury and high blood pressureMiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN.Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.Cathelicidin PR-39 peptide inhibits hypoxia/reperfusion-induced kidney cell apoptosis by suppression of the endoplasmic reticulum-stress pathway.Targeting transgene to the heart and liver with AAV9 by different promoters.Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression.Optimization of renal transfection using a renal suction-mediated transfection method in mice.Nephron segment-specific gene expression using AAV vectors.Efficient Gene Transfer to Kidney Mesenchymal Cells Using a Synthetic Adeno-Associated Viral Vector
P2860
Q27318007-7BE4C80F-B966-4D86-ABED-51BBBA981F5BQ34556913-4B5CAEEC-18DA-4C9A-9E61-82EB09DF6DE6Q35078590-5F45C4DE-7E9E-4290-827F-AF06DE428118Q35184168-3A97C49A-E6A1-44B8-9F02-A32D6D0822E3Q35568513-9FDAC0EA-795B-4D63-8B6B-91C7DB85BE3EQ36055431-D92B689F-C51B-4FBC-91F0-A695B8BD2BBBQ37041512-3FDEA62F-185E-49E6-9B56-9741258A4DDBQ37706642-E88C2CAE-2163-47E8-A8E9-EE17837F6596Q37959165-2E91C9E2-E11B-4900-95A0-2E81B31E0D33Q39648006-0EC9CB3A-3765-4525-8B34-BB84BCE1E4DEQ40738027-1928E984-D400-4235-BC0C-8598A380530DQ42768559-5CBC59AC-E2C1-4A32-B2B2-4EF4423ECBE7Q45879407-C17D23A8-DBEB-4BFB-A05C-BF9E7D5AEDC9Q50178823-8344BA82-7886-4C74-88A8-2BE9127B1AD2Q57164418-E8A8F265-F1CB-4A4A-9803-71A29CDD0CA1
P2860
Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Combined paracrine and endocri ...... he treatment of renal fibrosis
@ast
Combined paracrine and endocri ...... he treatment of renal fibrosis
@en
Combined paracrine and endocri ...... he treatment of renal fibrosis
@nl
type
label
Combined paracrine and endocri ...... he treatment of renal fibrosis
@ast
Combined paracrine and endocri ...... he treatment of renal fibrosis
@en
Combined paracrine and endocri ...... he treatment of renal fibrosis
@nl
prefLabel
Combined paracrine and endocri ...... he treatment of renal fibrosis
@ast
Combined paracrine and endocri ...... he treatment of renal fibrosis
@en
Combined paracrine and endocri ...... he treatment of renal fibrosis
@nl
P2093
P2860
P356
P1433
P1476
Combined paracrine and endocri ...... he treatment of renal fibrosis
@en
P2093
Hans-Peter Dienes
Hildegard Büning
Ingo Strack
Jochen W U Fries
Margarete Odenthal
Marianna Hösel
Melanie Scheffler
Oliver Coutelle
Roswitha Nischt
Stephanie Schievenbusch
P2860
P304
P356
10.1038/MT.2010.71
P577
2010-04-27T00:00:00Z